BIOATLA INC

BCABNASDAQ

🏆 #5322 by market capEarnings Nov 11US Equity

$1.74▲ $0.55 (+31.44%)

Live

🔔

Track BCAB

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 31.4%

7d▼ 3.1%

14d▼ 3.1%

30d▼ 3.1%

ytd▼ 93.9%

1y▼ 95.1%

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

-81.8%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

0.3x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $1.71 – $1.75
52-Week Range: $1.07 – $71.50
Volume: $2.59B
Avg Volume: $3.22B
Shares Outstanding: 1.7M
Next Earnings: Nov 18, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $7M
P/E Ratio: —
P/S Ratio: 0.3x
EPS (TTM): $-25.56
Dividend Yield: —
Dilution (1yr): +17.8%

Why Investors Own BCAB

✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIOATLA INC

BCAB

Financial Trends

Revenue

$2M▼ −81.8% YoY

Gross Margin

-2053.7%▼ −2342.2% YoY

Operating Income

−$59M▼ −19.8% YoY

Free Cash Flow

−$48M▼ −33.0% YoY

Shares Outstanding

1.2M▲ +17.8% YoY

Net Cash

$918K▼ −$47M YoY

StockOtter · stockotter.space

About BIOATLA INC

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

🦦